The ATP5IF1 Knockout HEK293T Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HEK293T human embryonic kidney epithelial cell line, engineered to disrupt the endogenous ATP5IF1 gene. This loss-of-function model provides researchers with a genetically defined system to interrogate the role of the ATPase inhibitory factor 1 in mitochondrial bioenergetics and cellular stress responses. The polyclonal nature of the knockout pool ensures a heterogeneous population of edited cells, facilitating robust functional studies without the artifacts associated with single-cell clonal selection. The product is designed for advanced biomedical research applications, including metabolic inhibitor screening and mechanistic dissection of mitochondrial dysfunction.
The host HEK293T cell line is a widely utilized human embryonic kidney epithelial derivative that expresses the SV40 large T antigen, enabling high-efficiency transfection and robust protein production. Originally generated by transformation of HEK293 cells with sheared adenovirus type 5 DNA, this line retains key renal epithelial characteristics while supporting rapid growth and scalable culture conditions. Its high transfection efficiency and compatibility with lentiviral and retroviral packaging make it a preferred chassis for genetic perturbation studies, particularly in mitochondrial biology, where transient overexpression and stable knockout models are routinely employed.
ATP5IF1 encodes the natural inhibitor of the mitochondrial F1Fo ATP synthase (Complex V), a critical regulator of oxidative phosphorylation. Under conditions of low mitochondrial membrane potential, the encoded protein binds to the F1 catalytic domain, preventing ATP hydrolysis and preserving the integrity of cristae architecture. Mechanistically, ATP5IF1 is regulated upstream by factors including HIF1A, AMP-activated protein kinase (AMPK), reactive oxygen species (ROS), and hypoxia, and its activity directly modulates ATP synthase function, cytochrome c release, and ROS production. The protein interacts with F1-ATPase subunits, cytochrome c, and members of the Bcl-2 family such as BAX and BCL2, positioning it at a nexus of metabolic and apoptotic signaling. Within the broader oxidative phosphorylation pathway, ATP5IF1 cooperates with subunits like ATP5A1, ATP5F1B, and ATP5F1C to govern energy transduction and mitochondrial remodeling.
In the HEK293T background, knockout of ATP5IF1 confers pronounced sensitivity to metabolic stress by promoting the reversal of ATP synthase activity under compromised membrane potential, leading to accelerated ATP depletion and altered mitochondrial bioenergetics. This sensitization is accompanied by measurable changes in cristae morphology and enhanced susceptibility to intrinsic apoptosis, as Bcl-2 family-dependent cytochrome c release is dysregulated. The high transfection efficiency of HEK293T cells further enables combinatorial perturbations??such as co-overexpression of protective BCL2 variants or pharmacological AMPK activators??allowing researchers to dissect pathway crosstalk with precision. The polyclonal knockout population also serves as a valuable tool for pooled CRISPR screens and for validating small-molecule modulators of the ATP synthase inhibitory axis.
This product is ideally suited for a wide range of experimental paradigms, including mitochondrial bioenergetics profiling using Seahorse respirometry to measure oxygen consumption and ATP production rates, analysis of ATP synthesis/hydrolysis kinetics via luciferase-based assays, and imaging-based assessment of cristae architecture and mitochondrial membrane potential with dyes such as JC-1 or TMRM. Additional applications encompass apoptosis pathway dissection through annexin V staining and cytochrome c release immunofluorescence, as well as western blotting to confirm loss of ATP5IF1 protein. The model also supports cancer metabolism research and phenotypic screening of metabolic inhibitors that target the mitochondrial depolarization response. For further details and technical support, please contact Ascent Research.
